Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lanza, Francesco
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Recruiting	3	550	Europe, Canada, US, RoW	Tamibarotene, SY-1425, Placebo, Azacitidine	Syros Pharmaceuticals	Myelodysplastic Syndromes	11/24	02/29
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML	Recruiting	3	322	Europe, Canada, US	Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF	Arog Pharmaceuticals, Inc.	Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	10/24	10/24
PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera	Completed	N/A	1150	Europe		IRCCS Azienda Ospedaliero-Universitaria di Bologna	Polycythemia Vera	12/23	12/23
INO-CD22, NCT03898128: ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate	Recruiting	N/A	120	Europe	Anti-CD22 Immunotoxin	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	Acute Lymphoblastic Leukemia	06/21	09/21
AL-TOMICA, NCT06626893: Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention	Recruiting	N/A	100	Europe	Functional tests, Next Generation Sequencing analysis, Microvesicles analysis	Azienda Ospedaliero-Universitaria di Parma	Myeloid Leukemia, Acute, Leukemia, Acute Lymphoblastic	03/25	03/25
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera	Recruiting	N/A	1055	Europe		IRCCS Azienda Ospedaliero-Universitaria di Bologna	Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis	05/32	05/32
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance	Recruiting	N/A	250	Europe		Ospedale di Circolo - Fondazione Macchi	SARS-CoV-2 Infection, Hematological Malignancies	10/22	10/22
INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies	Recruiting	N/A	2000	Europe	clinical data and sample collection	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna	Haematologic Disease, Haematological Malignancy	02/25	02/25
Immovili, Annalisa
INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies	Recruiting	N/A	2000	Europe	clinical data and sample collection	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna	Haematologic Disease, Haematological Malignancy	02/25	02/25